研究生教育

 联系方式

 杭州市解放路88号，浙江大学医学院附属第二医院门诊楼1104室

 消化实验室。

 Email: drylzhu@163.com；ylzhu@aliyun.com.

 Tel:86-571- 7767061, 

 Fax:86-571-87214404.

 主要履历和经历

 1999.9-2001.7  浙江大学医学院攻读消化病学硕士研究生，导师：钱可大教授；

 2001.9-2004.7  浙江大学医学院攻读肿瘤学学博士研究生，导师：郑树教授。

 1988.8--迄今  浙江大学医学院附属第二医院工作。

 主要研究领域

1).胃肠癌癌变和胃肠癌肿瘤干细胞分子机制研究；

2). 幽门螺杆菌分子致病(癌变)机制研究。

 主要承担课题

 1).大肠癌干细胞特征性分选标志鉴定及其转移潜能相关的关键功能靶蛋白筛检研究国家自然基金30万2007-2009负责人

 2). Nrip2选择性抑制大肠癌干细胞增殖和致瘤性的分子机制和关键作用靶蛋白鉴定国家自然基金34万2011-2013负责人

 3). ANKRD22调控结直肠癌细胞重新获得干细胞特性的关键靶分子及其作用机制研究

 国家自然基金74万2015-2018负责人

 4).新佐剂抗肿瘤多肽疫苗 科技部重大新药创制100万2014-2016   子课题负责人

 5). 肿瘤微环境调控结直肠癌细胞重新获得干细胞特性新分子ARRDC4作用机制研究 国家自然基金59万2017-2020负责人

 6).消化道肿瘤诊治生物标志物验证及应用研究 科技部13.5重大项目 20万2017-2020  子课题

 7).线粒体重编程新分子FAM227A促进结直肠癌细胞重新获得干细胞特性作用机制研究。国家自然基金57万2018-2022负责人

 8).朱永良研究团队  浙江省自然基金杰出人才项目35万2010-2012负责人

 9). 免疫、细胞与基因治疗新技术研究-新型人肿瘤 MICAα3 纳米单抗的研发及其抗转移效应评价浙江省科技厅重点研发项目200万2020-2022负责人

 学术兼职

 1). 中国抗癌协会肿瘤标志分会青年委员；

 2). 浙江省临床免疫学会副主任委员；

 3).浙江省免疫学会理事；

 4). 中国转化医学干细胞分会委员；

 5). World J Gastrointest Pathophysiology杂志编委；

 6). World J Gastrointest Endoscopy杂志编委；

 7). 世界华人消化杂志编委。

获得的奖励

 1). 应用一种新的病毒文库技术用于筛选大肠癌转移相关基因。2009年浙江省科学技术进步三等奖  第1作者          

 2).胃肠癌发病相关病因—饮不洁水和幽门螺杆菌感染研究。2012年浙江省科学技术进步三等奖  第1作者

专利

 1). 朱永良*，柳景文。以ANKRD22为靶标在制备胃肠粘膜修复保护剂中的应用。国家发明专利，申请号：201910878139.9

 2). 朱永良*，柳景文，朱悦。作为ANKRD22抑制剂的先导化合物及其应用。国家发明专利，申请号：202010113832.X

 3).朱永良*，秦光明，吴佳。检测可溶性异常糖基化修饰CD58分子的胶乳微球交联特异性单克隆或多克隆抗体的制备方法。授权发明专利，专利号：CN 105353117B。

主要论文

1). Pan TH, Liu JW, Xu S, Yu Q, Wang HP, Sun HX, Wu J, Zhu Y, Zhou JW*, Zhu Y*.ANKRD22, a novel tumor microenvironment-induced mitochondrial protein promotes metabolic reprogramming of colorectal cancer cells. Theranostics. 2020, 10: 516-536.(Corresponding author)

2). Wen Z, Xu S, Jiang Q, Zhu L,Feng S, Zhao Y, Wu J, Dong Q,Mao J*, Zhu Y*.Interaction between NRIP2 and ROR, a novel mechanism, involved in the self-renewal of tumor-intiating cell of colorectal cancer. Molecular Cancer.2017, 16: 20.(Corresponding author)

3).Pan T, Xu J, Zhu Y*. Self-renewal molecular mechanisms of colorectal cancer stem cells. Int J Mol Med. 2017, 39:9-20. (Corresponding author)

4). Xu S, Wen ZZ, Feng S, Zhu L, Mao J, Cai J, Zhu Y. CD58, a novel surface marker, promotes self-renewal of tumor-intiating cells in colorectal cancer. Oncogene 2015, 34, 1520-1531. (Corresponding author)  

5). Wu J, Pan TH, Xu S, Jia LT, Zhu LL, Mao JS, Zhu YL*, Cai JT. The virus-induced protein APOBEC3G inhibits anoikis by activation of Akt kinase in pancreatic cancer cells. Sci Rep. 2015;5:12230. (Corresponding author)

6). Wu J, Ji X, Zhu Y. Up-regulation of microRNA -1290 impairs cytokinesis and  affects the reprogramming of colon cancer cells. Cancer Letters 2013, 329:155-163. (Corresponding author)

7). Zhu Y, Jiang Q, Lou X, et al. MicroRNAs up-regulated by CagA of Helicobacter pylori induce intestinal metaplasia of gastric epithelial cells. PLoS One. 2012, 7:e35147.  (IF：4.092/2012)   

8). Tao H, Zhu Y. Colorectal cancer stem cell: a potential therapeutic target. Clin Transl Oncol. 2011, 13:833-838. (Corresponding author)         

9).Wu J, Xu S, Zhu Y. Helicobacter pylori CagA: a critical destroyer of the gastric epithelial barrier. Dig Dis Sci. 2013, 58:1830-1837. (Corresponding author)

10). Wang Y, Zhu Y, Qiu F, Zhang T, Chen Z, Zheng S, Huang J. Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells. Carcinogenesis 2010, 31:1376-13780. (Co-first author)  

11).Ding K, Su Y, Pang L, Lu Q, Wang Z, Zhang S, Zheng S, Mao J, Zhu Y. Inhibition of apoptosis by downregulation of hBex1, a novel mechanism, contributes to the chemoresistance of Bcr/Abl+ leukemic cells.Carcinogenesis. 2009, 30:35-42. (Corresponding author)  

12). Mao J, Xu Z, Fang Y, Wang H, Xu J, Ye J, Zheng S, Zhu Y. Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation.Cancer Sci. 2008, 99:2120-2127. (Corresponding author)

13). Zhu Y, wang CH, Huang J, Ge Z, Dong Q, Zhong X, Su YY, Zheng S. The helicobacter pylori virulence factor CagA promotes Erk1/2-mediated Bad phosphorylation in lymphocytes: a mechanism of CagA inhibited lymphocyte apoptosis. Cellular Microbiology, 2007, 9: 952-961.  

14). Jiang T, Zhu Y, Luo C, Lu X, Huang J. Matrine inhibits the activity of translation factor eIF4E through dephosphorylation of 4E-BP1 in gastric MKN45 cells. Planta Med, 2007, 73:1176- 1181.

15).Zhu Y, Zhong X, Zheng S, Du Q, Xu W.Transformed immortalized gastric epithelial cells by virulence factor CagA of Helicobacter pylori through Erk mitogen-activated protein kinase pathway. Oncogene, 2005, 24:3886-3895.

16). Zhu Y, Zhong X, Zheng S, Ge Z, Du Q, Zhang S. Transformation of immortalized colorectal crypt cells by microcystin involving constitutive activation of Akt and MAPK cascade. Carcinogenesis, 2005, 26:1207-1214.  

17).Zhu YL, Zheng S, Qian KD, Fang PC. Biological activity of the virulence factor cagA of Helicobacter pylori. Chin Med J, 2004, 117:1330-1333.  

18).Zhu YL, Zheng S, Du Q, Qian KD, Fang PC. Characterization of CagA variable region of Helicobacter pylori isolates from Chinese patients. World J Gastroenterol, 2005, 11:880-884.  

19). Luo C, Zhu Y, Jiang T, Lu XY, Zhang W, Jing QF, Li J, Pang LR, Chen KJ, Qiu FM, Yu XY, Yang JH, Huang J. Matrine induced gastric cancer MKN45 cells apoptosis via increasing pro-apoptotic molecules of Bcl-2 family. Toxicology. 2007, 229: 245-252. (IF：2.584/2005)

20).Zhong X, Zhu Y, Lu Q, Zhang JW, Ge Z, Zheng S. Silymarin causes caspases activation and apoptosis in K562 leukemia cells through inactivation of Akt pathway. Toxicology. 2006, 227:211-216.